We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Highlights Importance of Regular Lung Cancer Screenings for Higher Risk Patients

By LabMedica International staff writers
Posted on 29 Aug 2016
Researchers have found that patients who tested negative for lung cancer (LC) in an LDCT (low-dose helical computed tomography) screening, but later went on to develop lung cancer within the following two years, had poorer outcomes than patients who initially had a non-cancerous positive screen test result.

Lung cancer is one of the most complex cancers, both at the molecular level and through its clinical behavior. More...
Based on the large randomized “National Lung Screening Trial” study, the US Preventive Services Task Force recommends regular LC screenings with LDCT for people between ages 55-74 who have smoked at least one pack of cigarettes per day for 30 years or more. The recommendations also include heavy smokers who have quit within the past 15 years.

The new study, by researchers at the H. Lee Moffitt Cancer Center & Research Institute (Tampa, FA, USA), used the data from the National Lung Screening Trial to determine the outcomes of patients screened by LDCT according to their initial 12- and 24-month screening results. They found that patients who had a negative initial screening but tested positive for lung cancer at the 12- or 24-month screen had lower survival and higher mortality rates than patients who had a positive initial screen that was a non-cancerous abnormality but developed lung cancer in subsequent screens.

“Our findings suggest that individuals who originally present with negative screens and develop lung cancer 12 or 24 months later develop faster growing, more aggressive cancers that arose from a lung environment previously lacking abnormalities,” said Matthew B. Schabath, PhD, of Moffitt’s Cancer Epidemiology Program. The data also highlight the importance of continued lung cancer screening in high-risk patients. “Although tobacco cessation is one of the most important ways to reduce your risk of lung cancer, screening is a proven method to detect lung cancer earlier when it is easier to treat. Moreover, screening is not a one-time event. For it to be effective, high-risk individuals need to be screened on regular yearly intervals,” said Dr. Schabath.

The study, by Schabath MB et al, was published August 10, 2016, in the journal PLOS One.

Related Links:
H. Lee Moffitt Cancer Center & Research Institute



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.